San Francisco, CA – May 2026 – Remepy, a burgeoning health technology startup at the vanguard of integrating pharmaceutical and…
Read More

San Francisco, CA – May 2026 – Remepy, a burgeoning health technology startup at the vanguard of integrating pharmaceutical and…
Read More
While the clinical treatment of major depressive disorder has historically focused on stabilizing mood and emotional regulation, a significant portion…
Read More
Sanofi’s groundbreaking treatment for Pompe disease, Nexviazyme (avalglucosidase alfa), has achieved a significant milestone with the successful completion of the…
Read More
INDIANAPOLIS, IN – Eli Lilly and Company has announced groundbreaking Phase 3 trial results for its investigational drug, retatrutide, a…
Read More
A team of researchers from Carnegie Mellon University, in collaboration with experts from Stanford University and Purdue University, has published…
Read More
Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…
Read More
On May 13, 2024, at the 33rd European Congress on Obesity (ECO) held in Istanbul, Türkiye, groundbreaking Phase 3b trial…
Read More
On 12 May 2026, at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye, groundbreaking findings from the Phase…
Read More